Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
Medipharma, a Japanese site management organization (SMO), has initiated bankruptcy proceedings after it was found to have violated good clinical practice (GCP) regulations, including by falsifying clinical trial data. The Tokyo District Court approved the initiation of the proceedings as…
To read the full story
Related Article
- Medipharma Altered Data in at Least 7 Clinical Trials: MHLW
November 28, 2023
- Medipharma Might Face Administrative Penalty over Trial Data Tampering
October 18, 2023
BUSINESS
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
- Chugai Files Enspryng for MOGAD Relapse Prevention in Japan
August 3, 2026
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…